PIK3CA and ovarian cancer: Aberrant activation of PI3K (e.g., PIK3CA mutations), which is detected in many ovarian cancers, can result in inhibitory phosphorylation of GSK3β, rendering it unable to phosphorylate β-catenin and thus ultimately preventing β-catenin degradation [35].